Genocea to Present at the 20th Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13th at 2:15 P.M. ET.

A live webcast of the presentation will be available "Events and Presentations" tab of the investor relations section of the Genocea website at http://ir.genocea.com. Following the conclusion of the conference, the presentation will remain archived on the Genocea website for approximately 90 days.

About Genocea Biosciences, Inc.Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our proprietary ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, Inhibigens™, that drive pro-tumor immune responses. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our adoptive T cell therapy using neoantigen-targeted peripheral cells for which we are commencing a Phase 1/2a clinical trial. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in identifying meaningful therapies. To learn more, please visit https://www.genocea.com.

Investor Contact:Dan Ferry617-430-7576[email protected]

Source: Genocea Biosciences, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
• Best Crypto Presale: AlphaPepe Nears $2.5M as Buyers Race the August 26 Presale Closure Timeline
• XRP Price Prediction Turns Explosive at $1.48 While Pepeto Wallets Rush the Presale Before Listing